期刊
REDOX BIOLOGY
卷 22, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.redox.2019.101144
关键词
Chronic kidney disease; Mesenchymal stem cell; Tauroursodeoxycholic acid; Cellular prion protein; PINK1; Mitochondria; Mitophagy
资金
- Soonchunhyang University Research Fund, a National Research Foundation - Korean government [NRF-2017M3A9B4032528]
- Ministry of Health and Welfare
Although autologous human mesenchymal stem cells (hMSCs) are a promising source for regenerative stem cell therapy in chronic kidney disease (CKD), the barriers associated with pathophysiological conditions limit therapeutic applicability to patients. We confirmed that level of cellular prion protein (PrPc) in serum was decreased and mitochondria function of CKD-derived hMSCs (CKD-hMSCs) was impaired in patients with CKD. We proved that treatment of CKD-hMSCs with tauroursodeoxycholic acid (TUDCA), a bile acid, enhanced the mitochondrial function of these cells through regulation of PINK1-PrPc-dependent pathway. In a murine hindlimb ischemia model with CKD, tail vein injection of TUDCA-treated CKD-hMSCs improved the functional recovery, including kidney recovery, limb salvage, blood perfusion ratio, and vessel formation along with restored expression of PrPc in the blood serum of the mice. These data suggest that TUDCA-treated CKD-hMSCs are a promising new autologous stem cell therapeutic intervention that dually treats cardiovascular problems and CKD in patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据